WASHINGTON, D.C. - A federal appeals court on May 10 affirmed a trial court's decision that refused to grant a pharmaceutical company's request for an anti-suit injunction, finding that the issues in an international arbitration and a U.S. patent infringement action were not the same (Sanofi-Aventis Deutschland GMBH v. Genentech Inc., et al., No. 2012-1454, Fed. Cir.; 2013 U.S. App. LEXIS 9494).